Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

MUOAge (years)44 ± 1332 ± 1153 ± 10n.sn.sn.sFemales: Males9:314:415:14: : : Weight (Kg)72.15 ± 11.89101.52 ± 13.92109.01 ± 21.520.0000520.000001n.sBMI25.37 ± 2.3837.84 ± 5.71239.02 ± 6.060.000001 < 0.000001n.sBiochemical parameters White blood cells (103/L)5.53 ± 1.596.86 ± 1.937.8 ± 2.16n.s0.010206n.s Platelets (103/L)203.92 ± 28.11250.67 ± 70.43254.59 ± 85.45n.s0.045552n.s Insulin (µU/mL)10.37 ± 6.4312.47 ± 8.3321.66 ± 13.09n.s0.009860n.s HbA1c (%)5.15 ± 1.855.22 ± 0.356.22 ± 1.39n.sn.s0.026480 25-OH Vitamin D (ng/mL)30.92 ± 10.8822.44 ± 7.6018.76 ± 8.45n.s0.026382n.s hsCRP (mg/L)2.59 ± 0.856.33 ± 5.165.86 ± 4.49n.s0.009860n.s ESR (mm/h)12.48 ± 10.5726.78 ± 17.6826.77 ± 20.15n.s0.040768n.s CRP (mg/g)40.58 ± 44.8186.23 ± 47.68102.95 ± 72.09n.s0.020526n.s GFR (mL/min)92.75 ± 12.68110.83 ± 19.1691.69 ± 16.18n.sn.s0.030379 HOMA-IR1.76 ± 1.442.47 ± 1.635.61 ± 3.39n.s0.0002180.008094 A/G ratio (%)1.52 ± 0.191.46 ± 0.191.23 ± 0.45n.s0.040768n.s Alpha 2%8.94 ± 1.039.92 ± 1.089.26 ± 3.520.019745n.sn.s Beta 1%6.00 ± 0.616.51 ± 0.745.72 ± 2.030.04906n.sn.s ACR (mg/g)6.75 ± 6.7011.61 ± 9.8323.17 ± 31.61n.s0.011994n.s Albumin %60.11 ± 2.9959.18 ± 3.3351.59 ± 18.09n.s0.0197020.035324 Total cholesterol (mg/dl)183.08 ± 30.09170.56 ± 26.70191.52 ± 36.44n.s0.0384560.028301 TG (mg/dl)91.00 ± 42.9391.28 ± 39.79132.97 ± 63.39n.s0.0200650.008126 ALT (U/L)29.25 ± 13.2628.83 ± 11.0143.24 ± 25.25n.s0.0265490.010287 AST (U/L)20.58 ± 5.4018.83 ± 5.9824.86 ± 13.05n.sn.s0.037268 Calcemia (mg/dl)9.00 ± 0.4014.43 ± 22.619.30 ± 0.35n.s0,035551n.s TSH (mUI/l)1.41 ± 0.571.81 ± 0.972.60 ± 3.01n.s0,047811n.s FBG (mg/dl)100.17 ± 55.6392.06 ± 48.44123.72 ± 54.67n.sn.s0,044767Statistically significant corrected P-values (q-value < 0.05) were reported for healthy controls (HC), metabolically healthy obesity (MHO), and metabolically unhealthy obesity (MUO)n.s. not statistically significantWelch’ T-test corrected by Benjamini-Hochberg

Source: Subject characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

On the other hand, as defined, MHO patients were featured by only one or no comorbidity cardio-metabolic or respiratory diseases [].

Source: Methods.

A cross-sectional prospective observational study was performed in three different cohorts: healthy (HC), metabolically healthy obesity (MHO), and metabolically unhealthy obesity (MUO).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Gut microbiota and fecal volatilome profile inspection in metabolically healthy and unhealthy obesity phenotypes

Observational study · Journal of Endocrinological Investigation · 2024

Original publication title

Gut microbiota and fecal volatilome profile inspection in metabolically healthy and unhealthy obesity phenotypes

F. M. Calabrese; V. A. Genchi; N. Serale; G. Celano; M. Vacca; G. Palma; M. Svelto; L. Gesualdo; M. De Angelis; F. Giorgino; S. Perrini

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Compared to MHO, MUO subset symptom picture is featured by specific differences in gut pro-inflammatory taxa and metabolites that could have a role in the progression to metabolically unhealthy status and developing of obesity-related cardiometabolic diseases. The approach is suitable to better explain the crosstalk existing among dysmetabolism-related inflammation, nutrient intake, lifestyle, and gut dysbiosis.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Based on these differences, we are interested in deepening whether these obesity phenotypes could be linked to changes in microbiota and metabolome profiles. In this respect, the overt role of microbiota taxa composition and relative metabolic profiles is not completely understood. At this aim, biochemical and nutritional parameters, fecal microbiota, metabolome and SCFA compositions were inspected in patients with MHO and MUO under a restrictive diet regimen with a daily intake ranging from 800 to 1200 kcal.

Source: Objective

Abstract: What methods does the paper describe?

Blood, fecal samples and food questionnaires were collected from healthy controls (HC), and an obese cohort composed of both MHO and MUO patients. Most impacting biochemical/anthropometric variables from an a priori sample stratification were detected by applying a robust statistics approach useful in lowering the background noise. Bacterial taxa and volatile metabolites were assessed by qPCR and gas chromatography coupled with mass spectrometry, respectively. A targeted GC: MS analyses on SCFAs was also performed.

Source: Methods

Abstract: Results

Instructed to follow a controlled and restricted daily calorie intake, MHO and MUO patients showed differences in metabolic, gut microbial and volatilome signatures. Our data revealed higher quantities of specific pro-inflammatory taxa (i.e., Desulfovibrio and Prevotella genera) and lower quantities of Clostridium coccoides group in MUO subset. Higher abundances in alkane, ketone, aldehyde, and indole VOC classes together with a lower amount of butanoic acid marked the faecal MUO metabolome.

Source: Results

Abstract: Conclusions

Compared to MHO, MUO subset symptom picture is featured by specific differences in gut pro-inflammatory taxa and metabolites that could have a role in the progression to metabolically unhealthy status and developing of obesity-related cardiometabolic diseases. The approach is suitable to better explain the crosstalk existing among dysmetabolism-related inflammation, nutrient intake, lifestyle, and gut dysbiosis.

Source: Conclusions
Authors’ abstract

Background

People with metabolically healthy (MHO) and metabolically unhealthy obesity (MUO) differ for the presence or absence of cardio-metabolic complications, respectively.

Objective

Based on these differences, we are interested in deepening whether these obesity phenotypes could be linked to changes in microbiota and metabolome profiles. In this respect, the overt role of microbiota taxa composition and relative metabolic profiles is not completely understood. At this aim, biochemical and nutritional parameters, fecal microbiota, metabolome and SCFA compositions were inspected in patients with MHO and MUO under a restrictive diet regimen with a daily intake ranging from 800 to 1200 kcal.

Methods

Blood, fecal samples and food questionnaires were collected from healthy controls (HC), and an obese cohort composed of both MHO and MUO patients. Most impacting biochemical/anthropometric variables from an a priori sample stratification were detected by applying a robust statistics approach useful in lowering the background noise. Bacterial taxa and volatile metabolites were assessed by qPCR and gas chromatography coupled with mass spectrometry, respectively. A targeted GC: MS analyses on SCFAs was also performed.

Results

Instructed to follow a controlled and restricted daily calorie intake, MHO and MUO patients showed differences in metabolic, gut microbial and volatilome signatures. Our data revealed higher quantities of specific pro-inflammatory taxa (i.e., Desulfovibrio and Prevotella genera) and lower quantities of Clostridium coccoides group in MUO subset. Higher abundances in alkane, ketone, aldehyde, and indole VOC classes together with a lower amount of butanoic acid marked the faecal MUO metabolome.

Conclusions

Compared to MHO, MUO subset symptom picture is featured by specific differences in gut pro-inflammatory taxa and metabolites that could have a role in the progression to metabolically unhealthy status and developing of obesity-related cardiometabolic diseases. The approach is suitable to better explain the crosstalk existing among dysmetabolism-related inflammation, nutrient intake, lifestyle, and gut dysbiosis.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40618-024-02379-2.

Publication and source details

Original title: Gut microbiota and fecal volatilome profile inspection in metabolically healthy and unhealthy obesity phenotypes

F. M. Calabrese; V. A. Genchi; N. Serale; G. Celano; M. Vacca; G. Palma; M. Svelto; L. Gesualdo; M. De Angelis; F. Giorgino; S. Perrini

Journal of Endocrinological Investigation · 2024

© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100003407Ministero dell’Istruzione, dell’Università e della RicercaARS0101220De Angelis M. Università degli Studi di Bari Aldo Moro

Open access funding provided by Università degli Studi di Bari Aldo Moro within the CRUI-CARE Agreement.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T10:54:47.528302+00:00

DOI: 10.1007/s40618-024-02379-2 · PMC11549234